Conflicts of interest (COI) & CRO belong to the pharmaceutical Company (CRO b2Ph [Regulatives / Guidelines]

posted by wienui  – Germany/Oman, 2022-07-07 22:48 (598 d 20:22 ago) – Posting: # 23114
Views: 2,082

Dear Ohlbe ,Divyen & all,

Yes, the pot is full and this calls us (Regulatory + Industry) to unite to fight those types of frauds, otherwise, the patient will lose complete confidence in the drugs, especially the Generic drugs.
But let us return to the main topic, should the regulatory authorities refuse the submission and acceptance of BE studies that have been performed in a CRO belonging to the sponsor? are there any references? or are there other opinions other than that?

Cheers,
Osama

Complete thread:

UA Flag
Activity
 Admin contact
22,912 posts in 4,806 threads, 1,635 registered users;
28 visitors (0 registered, 28 guests [including 5 identified bots]).
Forum time: 18:10 CET (Europe/Vienna)

[…] an inappropriate study design is incapable of answering
a research question, no matter how careful the subsequent
methodology, conduct, analysis, and interpretation:
Flawless execution of a flawed design achieves nothing worthwhile.    J. Rick Turner

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5